Venture Capital news from FierceBiotech
NewsElixir drops IPO, Aldagen launches IPO
Elixir Pharmaceuticals has dropped its bid for an $86 million IPO, saying that Read more...
Pfizer spins off Esperion as VCs ante up $22.75M
Pfizer has spun of Esperion Therapeutics into a new biotech company aiming to develop new therapies for cardiovascular and metabolic disease. A syndicate of investors funded the deal. Pfizer sold Read more...
Concert tech strikes chord with $37M VC round
Even before its first compound hits the clinic, Concert Pharmaceuticals is having no trouble raising venture funds. The Lexington, MA-based developer has just ginned $37 million in a new venture Read more...
$117M venture firm takes flight in Europe
A group of Elan veterans in Ireland have launched a €75 million ($117 million) venture fund for life sciences companies. Fountain Healthcare Partners, based in Dublin, plans to sink anywhere from Read more...
Millennium's Levin uses golden touch to fund start-up
Mark Levin earned a reputation for a colorful personality with an incredible knack for raising cash as co-founder of Millennium Pharmaceuticals. Two weeks ago, Takeda helped seal Levin's reputation Read more...
Nuon gets $27M to fund a mid-stage trial
Frazier Healthcare Ventures and Domain Associates have joined forces to lead a $27 million Series B for Nuon Therapeutics, a San Mateo, CA-based developer working on new therapies for autoimmune and Read more...
Aldagen gets $18.4M in fourth round
With the help of Intersouth Partners, Tullis-Dickerson, Harbert Venture Partners and The Aurora Funds, stem cell technology company Aldagen has closed an $18.4 million fourth round of funding. The Read more...
Argos garners $35.2M in third round
TVM Capital led a hefty $35.2 million third round of venture capital for Colorado's Argos Therapeutics. The funding will be used to support Argos' Phase II trial of Arcelis immunotherapy drug Read more...
In VC market, life sciences dominate
In the first quarter of this year, venture capital investment dipped 5 percent to $7.1B, signaling that the current economic slump could have an impact on venture financing. However, there was still Read more...
Resolvyx rounds up $25M
Bedford, MA-based Resolvyx has garnered $25 million in a second round of venture capital. QVT Financial LP led the funding round. The money will be used to accelerate Resolvyx's preclinical Read more...
| Press ReleasesResolvyx Pharmaceuticals Raises $25 Million in Series B Financing Resolvyx Pharmaceuticals Raises $25 Million in Series B Financing 4/22/2008 BEDFORD, Mass. -- Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that it has Read more... Venture Capital Investment Declines in Q1 2008 According to the MoneyTree Report Venture Capital Investment Declines in Q1 2008 According to the MoneyTree Report Life Sciences, Semiconductors Have Strong Quarter WASHINGTON, DC--(Marketwire - April 21, 2008) - Venture capitalists Read more... PRESS RELEASE: PregLem Announces CHF 36 Million Series B Funding PregLem Announces CHF 36 Million Series B Funding GENEVA -- PregLem, a Swiss specialty biopharmaceutical company focused on the development and commercialization of innovative therapeutic compounds Read more... PRESS RELEASE: BioVex Closes Second Round of Series E Financing BioVex Closes Second Round of Series E Financing Second and Final Close Completes $35 Million Financing Woburn, MA, November 15 2007 – BioVex Inc, a clinical stage company developing new Read more... PRESS RELEASE: Zosano Pharma Announces Funding Close Totaling $90 Million Zosano Pharma Announces Funding Close Totaling $90 Million FREMONT, Calif. -- Zosano Pharma, Inc., an emerging specialty pharmaceutical company focused on developing better pharmaceutical products Read more... |
Get more Venture Capital coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight